- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06103175
Observational and Prospective Study of Hepatic Steatosis and Related Risk Factors Using Ultrasound and Artificial Intelligence (ST-AI)
Study Overview
Status
Conditions
Detailed Description
In recent years, ultrasound has taken on a predominant role in the evaluation of liver steatosis, as it is a non-invasive, non-irradiating method that is easily reproducible and inexpensive. Of particular effectiveness is the use of the hepatorenal index, evaluated as the intensity ratio (echogenicity) between the hepatic parenchyma and the renal cortical parenchyma. The main limitations of detecting the hepato-renal index during abdominal ultrasound, however, are operator dependence and the use of a relatively long time span to complete the sequence of operations and calculations required to determine the index itself. The use of Artificial Intelligence (AI) techniques for image analysis in the medical field is yielding excellent results. AI-based algorithms are increasingly a powerful tool that allows the physician to improve their performance in terms of speed and accuracy of clinical evaluations. Today, there is already evidence of the effectiveness of using AI on ultrasound images for clinical evaluations. The use of AI as an aid in diagnosing liver diseases through ultrasound is still under-researched. The hypothesis to be tested is the utility that AI can have in the evaluation, its general and specific uses in reducing calculation times of the hepatorenal index.
In this study, 134 patients were enrolled with no clinical suspicion of liver steatosis. All patients underwent abdominal ultrasonography (US) and magnetic resonance imaging fat fraction (MRI-PDFF), assumed as reference technique to evaluate the grade of steatosis. The hepatorenal index (US) was manually calculated (HRIM) by 4 skilled operators. An automatic hepatorenal index calculation (HRIA) was also obtained by an algorithm. The accuracy of HRIA to discriminate different grades of fatty liver was evaluated by Receiver operating characteristic (ROC) analysis using MRI-PDFF cut-offs.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
BA
-
Bari, BA, Italy, 70124
- Department of Department of Precision and Regenerative Medicine and Ionian Area (DiMePre-J - Clinica medica "A. Murri"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age between 18-70 years
- MRI regardless of clinical indications,
- written informed consent
Exclusion Criteria:
- cirrhosis
- hepatocellular carcinoma or any liver tumours,
- absence of the right kidney
- previous liver transplantation
- large liver cysts or kidney cysts
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hepato-renal index calculation
Time Frame: 4 months
|
Calculation of the Hepatorenal Index manually and automatically using the AI-based algorithm.
|
4 months
|
|
Magnetic Resonance scanning and fat percentage evaluation
Time Frame: 4 months
|
Proton Density Fat Fraction MRI scans (MRI-PDFF) to evaluate the liver fat percentage as the average value of percentage of fat evaluated for each liver segment
|
4 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AI-steatosis
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Steatoses
-
Assiut UniversityNot yet recruiting
-
Medical College of WisconsinRecruiting
-
Federal State Budgetary Scientific Institution...CompletedLiver Fibrosis | Chronic Liver Disease | Liver SteatosesRussian Federation
-
Stanford UniversityCompletedLiver Cirrhosis | Liver SteatosesUnited States
-
Dr Abdurrahman Yurtaslan Ankara Oncology Training...CompletedLiver SteatosesTurkey
-
AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE...RecruitingLiver Diseases | Liver Failure | Liver Cirrhosis | Liver Metastases | Liver Cancer | Liver Transplant Rejection | Liver SteatosesChina
-
Anton SkaroRecruitingNAFLD | Liver Metastasis Colon Cancer | Liver SteatosesCanada
-
Beijing Jishuitan HospitalChinese PLA General Hospital; Huashan Hospital; First Affiliated Hospital Xi'an... and other collaboratorsRecruiting
-
King's College Hospital NHS TrustSamsung MedisonRecruitingHepatitis | Liver Fat | NAFLD | Fibrosis, Liver | Liver Disease Chronic | Liver Steatoses | NASH With FibrosisUnited Kingdom
-
Fibronostics USA, IncCompletedNon-Alcoholic Fatty Liver Disease | Non-Alcoholic Steatohepatitis | Liver Inflammation | Liver Fibroses | Liver SteatosesUnited States